References
- Asai T, Miyazawa S, Maeda N, et al. (2008). Antineovascular therapy with angiogenic vessel-targeted polyethyleneglycol-shielded liposomal DPP-CNDAC. Cancer Sci 99:1029–33
- Katanasaka Y, Ida T, Asai T, et al. (2008). Antiangiogenic cancer therapy using tumor vasculature-targeted liposomes encapsulating 3-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one, SU5416. Cancer Lett 270:260–8
- Kikuchi H. (2010). Chuusyazai (Tokusyu Seizai) (Injections (specialty formulations)): Zaikei to Seizaihou (Dosage forms and formulation methods). In: Itai S, ed. Handbook of pharmaceutical machinery and engineering. 2nd ed. Tokyo, Japan: Chijin syokan, 666–77
- Maeda N, Takeuchi Y, Takada M, et al. (2004a). Synthesis of angiogenesis-targeted peptide and hydrophobized polyethylene glycol conjugate. Bioorg Med Chem Lett 14:1015–17
- Maeda N, Takeuchi Y, Takada M, et al. (2004b). Anti-neovascular therapy by use of tumor neovasculature-targeted long-circulating liposome. J Control Release 100:41–52
- Murase Y, Asai T, Katanasaka Y, et al. (2010). A novel DDS strategy, “dual-targeting”, and its application for antineovascular therapy. Cancer Lett 287:165–71
- Namba Y, Sakakibara T, Masada M, et al. (1989). 1-O-Palmitoyl-D-glucronate endows liposomes with long half-life in vivo. Chem Lett 12:2145–8
- Namba Y, Sakakibara T, Masada M, et al. (1990). Glucronate-modified liposomes with prolonged circulation time. Chem Lett 38:1663–6
- Oku N, Namba Y, Okada S. (1992). Tumor accumulation of novel RES-avoiding liposomes. Biochim Biophys Acta 1126:255–60
- Pastorino F, Brignole C, Marimpietri D, et al. (2003). Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res 63:7400–9